|Bid||52.73 x 3000|
|Ask||52.70 x 1300|
|Day's Range||52.16 - 53.55|
|52 Week Range||46.93 - 58.10|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||19.17|
|Forward Dividend & Yield||1.80 (3.45%)|
|Ex-Dividend Date||May 04, 2022|
|1y Target Est||64.13|
The early case for the mRNA-based Covid-19 vaccines was that the adaptability of the technology meant they could be updated to match the virus as it evolved.
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.